Drug profile · INN
ganciclovir
VITRASERT IMPLANT
ganciclovir (VITRASERT IMPLANT) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — ganciclovir
- US status
- approved
- Class
- Antiinfectives for systemic use (J05)
- Route
- OPHTHALMIC
- Patents
- 1
- Programs
- 5
- Data quality
- 0.84
Quick answer
ganciclovir (VITRASERT IMPLANT) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Human herpesvirus 1 DNA polymerase inhibitor
Primary target: DNA polymerase catalytic subunit
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is ganciclovir?
ganciclovir (VITRASERT IMPLANT) is a human herpesvirus 1 dna polymerase inhibitor. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for ganciclovir?
VITRASERT IMPLANT is a marketed brand name for ganciclovir. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ganciclovir?
ganciclovir has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.